Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer

Cancer Science

Volumn 98, Issue 3, 2007, Pages 380-386

  Sakuma, Michiko ^a   Akahira, Jun Ichi ^a   Ito, Kiyoshi ^a   Niikura, Hitoshi ^a   Moriya, Takuya ^a   Okamura, Kunihiro ^a   Sasano, Hironobu ^a   Yaegashi, Nobuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D2;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; CYCLINS; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PROGNOSIS; PROMOTER REGIONS (GENETICS); RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33846675127     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00394.x     Document Type: Article

References (35)

1. Akahira J, Yoshikawa H, Shimizu Y et al. Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study. Gynecol Oncol 2001; 81: 398-403.
2. Bonnefoi H, A'Hern RP, Fisher C et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999; 17: 767-75.
3. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-7.
4. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9.
5. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet 1997; 13: 444-9.
6. Razin A, Ceder H. DNA methylation and gene expression. Microbiol Rev 1991; 55: 451-8.
7. O'Doherty AM, Church SW, Russell SHE et al. Methylation status of oestrogen receptor-α gene promoter sequences in human ovarian epithelial cell lines. Br J Cancer 2002; 86: 282-4.
8. Rathi A, Virmani AK, Schorge JO et al. Methylation profiles of sporadic ovarian tumor and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002; 8: 3324-31.
9. Akahira J, Sugihashi Y, Suzuki T et al. Decreased expression of 14-3-3sigma is associated with advanced disease in human epithelial ovarian cancer: Its correlation with aberrant DNA methylation. Clin Cancer Res 2004; 10: 2687-93.
10. Dhillon VS, Shahid M, Husain SA. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in granulose cell tumors (GCTs) of ovarian origin. Mol Cancer 2004; 3: 33.
11. Messague J. G1 cell-cycle control and cancer. Nature 2004; 432: 298-306.
12. Zhang P. The cell cycle and development: Redundant roles of cell cycle regulators. Curr Opin Cell Biol 1999; 11: 655-62.
13. Sicinski P, Donaher JL, Geng Y et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996; 384: 470-4.
14. Meyyappan M, Wong H, Hull C, Raibowol KT. Increased expression of cyclin D2 during multiple status of growth arrest in primary established cells. Mol Cell Biol 1998; 18: 3163-72.
15. Evron E, Umbricht CB, Korz D et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001; 61: 2782-7.
16. Yu J, Leung WK, Ebert MPA et al. Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br J Cancer 2003; 88: 1560-5.
17. Virmani A, Rathi A, Heda S et al. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int J Cancer 2003; 107: 341-5.
18. Fackler MJ, McVeigh M, Evron E et al. DNA methylation of RASSF1A, HIN-1, RAR-b, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003; 107: 970-5.
19. WHO. Handbook for Reporting Results of Cancer Treatment. WHO Publication No. 48. Geneva: WHO, 1979.
20. Shimizu Y, Kamoi H, Amada S et al. Toward the developing of a universal grading system for ovarian epithelial carcinoma. Prognostic significance of histopathologic features - problems involved in the architectural grading system. Gynecol Oncol 1998; 70: 2-12.
21. Herman JG, Graff JR, Myohanen S et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islamds. Proc Natl Acad Sci USA 1996; 93: 9821-6.
22. Choi DS, Yoon S, Lee EY et al. Characterization of cyclin D2 expression in human endometrium. Gynecol Invest 2002; 9: 41-6.
23. Akahira J, Suzuki T, Ito K et al. Differential expression of progesterone receptor isoform A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res 2002; 93: 807-15.
24. Akahira J, Sugihashi Y, Ito K et al. Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer. Cancer Sci 2004; 95: 40-3.
25. Kamikihara T, Arima T, Kato K et al. Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer. Int J Cancer 2005; 115: 690-700.
26. Schwartsmann G, Fernandes MS, Schaan MD et al. Decitabine (5-Aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: Preliminary observations. Leukemia 1997; 11: S28-31.
27. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998; 58: 95-101.
28. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91: 11797-801.
29. Evron E, Dooley WC, Umbricht CB et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001; 357: 1335-6.
30. Silvestrini R, Daidone MG, Veneroni S et al. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 1998; 82: 159-67.
31. Akahira J, Inoue T, Suzuki T et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: Immunohistochemical and RT-PCR studies. Br J Cancer 2000; 83: 1488-94.
32. Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-91.
33. Chiang JW, Karlan BY, Cass L, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 2006; 101: 403-10.
34. Gifford G, Paul J, Vasey PA et al. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10: 4420-6.
35. Terasawa K, Sagae S, Toyota M et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 2004; 10: 2000-6.